Reducing levels of a spliceosome-associated factor, SYF2, attenuates TDP-43 pathology in models of diverse forms of ALS. Therefore, these findings by Linares et al. indicate that SYF2 suppression may function as a broadly acting therapeutic strategy for the treatment of ALS.
